ORDERING OF SEPARATE BATCHES Sample Clauses

ORDERING OF SEPARATE BATCHES. If GSK Canada provides Corixa with a binding forecast or order pursuant to Section 4.3(b) or 4.3(c), that if placed by Corixa with BI Pharma or Nordion, as applicable, would result in GSK Canada having an obligation to pay separate batch charges to Corixa pursuant to Section 6.7(b), then Corixa shall inform GSK Canada promptly after Corixa becomes aware of such circumstances and Corixa shall specify the deadline for GSK Canada to notify Corixa that it still wishes to place such binding forecast or order. If Corixa does not receive such notification from GSK Canada by such deadline, it shall not place such binding forecast or order with BI Pharma or Nordion, as applicable.
Sample 1
AutoNDA by SimpleDocs
ORDERING OF SEPARATE BATCHES. If GSK Canada provides Corixa with a binding forecast or order pursuant to Section 4.3(b) or 4.3(c), that if placed by Corixa with BI Pharma or Nordion, as applicable, would result in GSK Canada having an obligation to pay separate batch charges to Corixa pursuant to Section 6.7(b), then Corixa shall inform GSK Canada promptly after Corixa becomes aware of such circumstances and Corixa shall specify the deadline for GSK Canada to notify Corixa that it still wishes to place such binding forecast or order. If Corixa does not receive such notification from GSK Canada by such deadline, it shall not place such binding forecast or order with BI Pharma or Nordion, as applicable. ---------------------------------- * Confidential Treatment requested. 28. <PAGE> (f) ORDER CAUSING A BATCH SIZE INCREASE. If GSK Canada provides Corixa with a binding forecast or order pursuant to Section 4.3(b) or 4.3(c), that if placed in its entirety by Corixa with BI Pharma or Nordion, as applicable, would result in GSK Canada having an obligation to pay increased batch size charges to Corixa pursuant to Section 6.7(c), then Corixa shall inform GSK Canada promptly after Corixa becomes aware of such circumstances and Corixa shall specify the deadline for GSK Canada to notify Corixa that it still wishes to place the entirety of such binding forecast or order. If Corixa does not receive such notification from GSK Canada by such deadline, it shall only place with BI Pharma or Nordion, as applicable, that portion of such binding forecast or order that does not necessitate a larger batch size than would have been made if GSK Canada had not attempted to place any binding forecast or order for such period. 4.4
Sample 1

Related to ORDERING OF SEPARATE BATCHES

  • Supplier Selection If Customer selects a seat or galley supplier that is not on the Boeing recommended list, such seat or galley will become BFE and the provisions of Exhibit A, Buyer Furnished Equipment Provisions Document, of the AGTA will apply.

  • Form and Timing of Response (a) Intermediary agrees to provide, promptly upon request of the Fund or its designee, the requested information specified in paragraph 1 above. If requested by the Fund or its designee, Intermediary agrees to use best efforts to determine promptly whether any specific person about whom it has received the identification and transaction information specified in paragraph 1 is itself a financial intermediary (“indirect intermediary”) and, upon further request of the Fund or its designee, promptly either (i) provide (or arrange to have provided) the information set forth in paragraph 1 for those shareholders who hold an account with an indirect intermediary or (ii) restrict or prohibit the indirect intermediary from purchasing, in nominee name on behalf of other persons, securities issued by the Fund.

  • IMPORTANT INFORMATION ABOUT PROCEDURES FOR OPENING A NEW ACCOUNT To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial organizations to obtain, verify, and record information that identifies each person who opens an account. What this means for you: When you open an account, you are required to provide your name, residential address, date of birth, and identification number. We may require other information that will allow us to identify you.

  • Method of Selecting Types and Interest Periods for New Advances The Company shall select the Type of Advance and, in the case of each Eurodollar Advance, the Interest Period applicable thereto from time to time. The Company shall give the Agent irrevocable notice (a “Borrowing Notice”) not later than 12:00 noon (New York City time) on the Borrowing Date of each Floating Rate Advance and not later than 12:00 noon (New York City time) three (3) Business Days before the Borrowing Date for each Eurodollar Advance, specifying:

  • Compliance with Record Keeping Requirements Participating Dealer agrees to comply with the record keeping requirements of the Exchange Act, including but not limited to, Rules 17a-3 and 17a-4 promulgated under the Exchange Act. Participating Dealer further agrees to keep such records with respect to each customer who purchases Primary Shares, his suitability and the amount of Primary Shares sold, and to retain such records for such period of time as may be required by the Commission, any state securities commission, FINRA or the Company.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!